Vectormune ND a step towards control of Newcastle Disease

Size: px

Start display at page:

Download "Vectormune ND a step towards control of Newcastle Disease"

Magdalene Perry
5 years ago
Views:

1 Poultry Vaccinology Summit April 28-30, Budapest, Hungary Vectormune ND a step towards control of Newcastle Disease Yannick Gardin 1, Vilmos Palya 1, John Elattrache 1, Marcelo Paniago 2, Christophe Cazaban 2, Fernando Lozano 2, Pascal Paulet 3 1 Scientific and Innovation Department, 2 Global Veterinary Services Poultry department, 3 Poultry Franchise department. YG

2 The parameters of ND vaccination For the control of Newcastle Disease (ND) vaccination is a very efficacious tool, if complementary to:

3 The parameters of ND vaccination For the control of Newcastle Disease (ND) vaccination is a very efficacious tool, if complementary to: Good animal husbandry Stringent Biosecurity Effective Sanitary Police

4 The parameters of ND vaccination ND vaccination program must match the field disease pressure:

5 The parameters of ND vaccination ND vaccination program must match the field disease pressure: Low ND is a potential risk Medium ND is a real risk High ND is a strong risk

6 The parameters of ND vaccination Reliable vaccination against ND must take into account:

7 The parameters of ND vaccination Reliable vaccination against ND must take into account: YG Importance of vaccine administration including flock coverage Interference with Passive immunity (Maternally Derived Antibodies or MDA)

8 The parameters of ND vaccination The critical points regarding vaccine immunity against ND are:

9 The parameters of ND vaccination The critical points regarding vaccine immunity against ND are: Onset of Immunity (OOI) Level of Immunity (LOI) Duration of Immunity (DOI)

10 ND vaccines As of today, there are 2+1 categories of vaccines against ND:

11 ND vaccines As of today, there are 2+1 categories of vaccines against ND: Live attenuated Inactivated (killed) adjuvanted

12 ND vaccines As of today, there are 2+1 categories of vaccines against ND: Live attenuated Inactivated (killed) adjuvanted rhvt-f (Vectormune ND)

13 ND vaccines The classical ND vaccines Category + - Live Killed Fast OOI Local (& general Imm.) Long lasting Immunity Susceptible to MDA Post Vaccination Reactions Short lasting Immunity Susceptible to MDA Local reaction General Immunity only

14 ND vaccines Category + - Live Killed The classical ND vaccines Fast OOI Local (& general Imm.) Long lasting Immunity Susceptible to MDA Post Vaccination Reactions Short lasting Immunity Susceptible to MDA Local reaction General Immunity only

15 The problem of interference with MDA

16 The problem of interference with MDA Antibody titre* (10 log) serum tears YG < *ImmunoPeroxydase Monolayer Assay Age (days) (after P.H. Russel, 1993)

17 The problem of interference with MDA Live attenuated ND vaccines

18 The problem of interference with MDA % protection / challenge Live attenuated ND vaccines Chickens Control MDA with without Age (days) YG (after Bennejean G. et al., 1978)

19 The problem of interference with MDA % protection / challenge Live attenuated ND vaccines Chickens Vaccinated Control MDA with without Age (days) YG (after Bennejean G. et al., 1978)

20 The problem of interference with MDA % protection / challenge Live attenuated ND vaccines Chickens Vaccinated Control MDA with without Age (days) YG (after Bennejean G. et al., 1978)

21 The problem of interference with MDA Killed (inactivated) ND vaccines

22 % of protection The problem of interference with MDA Killed (inactivated) ND vaccines Killed vaccine - No MDA Killed vaccine - MDA Age at challenge (days) YG (after Bennejean G. et al., 1978)

23 The problem of interference with MDA rhvt-f (Vectormune ND) vaccine

24 The problem of interference with MDA rhvt-f (Vectormune ND) vaccine La Sota (Phylaxia) antigen YG (Extract from study SCI SSIU Ceva Phylaxia)

25 The problem of interference with MDA rhvt-f (Vectormune ND) vaccine La Sota (Phylaxia) antigen YG (Extract from study SCI SSIU Ceva Phylaxia)

26 The problem of interference with MDA rhvt-f (Vectormune ND) vaccine La Sota (Phylaxia) antigen YG (Extract from study SCI SSIU Ceva Phylaxia)

27 The problem of interference with MDA rhvt-f (Vectormune ND) vaccine La Sota (Phylaxia) antigen YG (Extract from study SCI SSIU Ceva Phylaxia)

28 Efficacy of Vectormune ND

29 Efficacy of Vectormune ND Laboratory trials in Thailand (vvndv)

30 Percentage of protection Efficacy of Vectormune ND Laboratory trials in Thailand (vvndv) VECT ORMUNE HVT-NDV Laboratory challenge trials in T hailand YG Vectormune HVT-NDV Cevac Vitapest L Cevac Vitapest L + Vectormune HVT-NDV Cevac Vitapest L + Cevac Broiler ND K Controls Age at challenge (days)

31 Efficacy of Vectormune ND Laboratory trials at SSIU Ceva Phylaxia

32 Efficacy of Vectormune ND Laboratory trials at SSIU Ceva Phylaxia - Commercial broilers (20 per group) - Vectormune ND SQ or in-ovo (-3d) - Challenge : EID50 Chimalhuacan NDV strain - at 3 or 4 or 6 weeks of age - IN + ON route - Oropharyngeal and Cloacal swabs taken 3 and 7 days PC - Virus quantification using RT-PCR

33 Efficacy of Vectormune ND Clinical protection YG

34 Efficacy of Vectormune ND Challenge at D28 * * * * * * * * Reduction of shedding

35 Efficacy of Vectormune ND Challenge at D28 * * * * * * * * Reduction of shedding

36 Efficacy of Vectormune ND Does it protect against various types of NDV? YG F insert 36

37 Efficacy of Vectormune ND Does it protect against various types of NDV? YG F insert 37 Yes!

38 Efficacy of Vectormune ND Does it protect against various types of NDV? YG Yes! F insert 38 Yes!

39 Efficacy of Vectormune ND Does it protect against various types of NDV? Yes! YG Yes! F insert 39 Yes!

40 Efficacy of Vectormune ND Does it protect against various types of NDV? Yes! Yes! YG Yes! F insert 40 Yes!

41 Efficacy of Vectormune ND Controlled trials at SSIU Ceva Phylaxia - Lohman Brown layer pullets with MDA - Vectormune ND (d1 SQ) - Vectormune ND (d1 SQ) + Cevac Vitapest L (ED) + Cevac ND IB EDS K (w15 IM) - Challenge : EID 50 Malaysian 2010 vvndv viscerotropic isolate (Genotype VII) - IN route (0,1 ml) - at 3, 4, 6, 10, 33, and 72 weeks of age

42 % Protection Efficacy of Vectormune ND Controlled trials at SSIU Ceva Phylaxia Protection of layers against vvndv challenge Vectormune HVT-NDV Vectormune HVT-NDV + Cevac Vitapest L + Killed Controls Age at challenge (in weeks) 33 72

43 Vectormune ND: vaccination programs Disease pressure MDA Vectormune ND Low O O Live ND Priming D1 Medium O O O Live ND boost D14-18 High O O O O

44 Conclusions: Vectormune ND YG Vaccine «take» is not prevented by MDA Vaccine take depends only on the quality of administration Administration can be done at the hatchery (in-ovo or SQ) i.e. in the most reliable way Early immunity can be re-inforced by MDA and live vaccine(s) if necessary Duration of immunity is outstanding Shedding of challenge virus is reduced

45 Conclusions: Vectormune ND A (major) step towards a better control of Newcastle Disease

46 THANK YOU FOR YOUR ATTENTION

RECOMBINANT VACCINES Live or Killed

Antigens and Vaccines Molecular biology drives Innovation Antigen Gene of Interest Recombination RECOMBINANT VACCINES Live or Killed Antigens and Vaccines Molecular biology drives Innovation Antigen Gene